Advertisement
Screener

ANEBULO PHARMACEUTICALS, INC. (ANEB) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

ANEBULO PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 90.00% for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-09-29

  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-12-31 was 90.00%, a 50.00% increase year-over-year.
  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 60.00%.
  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-12-31 was 60.00%, a 0.00% change year-over-year.
  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-09-30 was 60.00%, a 20.00% increase year-over-year.
  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 90.00%.
  • ANEBULO PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 50.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2025-06-3090.00%
10-K · filed 2025-09-29
2025-03-3190.00%
10-Q · filed 2025-05-13
2024-12-3190.00%
10-Q · filed 2025-02-14
90.00%
10-Q · filed 2025-02-14
2024-03-3160.00%
10-Q · filed 2025-05-13
60.00%
10-Q · filed 2025-05-13
2023-12-3160.00%
10-Q · filed 2025-02-14
60.00%
10-Q · filed 2025-02-14
2023-09-3060.00%
10-Q · filed 2024-11-13
2022-12-3160.00%
10-Q · filed 2024-02-13
2022-09-3050.00%
10-Q · filed 2023-11-14
2022-06-3050.00%
10-K · filed 2023-09-22
2022-03-3150.00%
10-Q · filed 2023-05-11
50.00%
10-Q · filed 2023-05-11
2021-12-3150.00%
10-Q · filed 2023-02-10
2021-03-3149.60%
10-Q · filed 2022-05-11
49.60%
10-Q · filed 2022-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Korsana Biosciences, Inc. (CYCN)United States$0.016B
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14